Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 9,944 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Infectious Clear all

Conditions: HIV Infections
Interventions: Aldesleukin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 17
States / cities: Los Angeles, California • Palo Alto, California • San Jose, California + 10 more

Conditions: Post-COVID-19 Condition, Post-COVID Condition, Post-COVID Syndrome, Long COVID, Chronic Fatigue, Chronic Fatigue Symptoms, Fatigue Post Viral
Interventions: REGENECYTE®; Biological
Lead sponsor: StemCyte, Inc.; Industry
Eligibility: 18 Years and older
U.S. locations: 2
States / cities: Miami, Florida • Miami Lakes, Florida

Conditions: HIV-1 Infection
Interventions: atorvastatin, placebo for atorvastin; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 30
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 21 more

Conditions: HIV Infection
Interventions: HPV vaccine for strains -6, -11, -16, and -18; Biological
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 16 Years to 23 Years · Female only
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 13
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 9 more

Conditions: Breast Cancer
Interventions: Chlorhexidine irrigation, triple antibiotic irrigation; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 81 Years · Female only
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Mycobacterium Avium-intracellulare Infection, HIV Infections, Pneumococcal Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 326 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2000
U.S. locations: 15
States / cities: San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 11 more

Conditions: Healthy Subjects, Infection, Human Immunodeficiency Virus
Interventions: Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg, Dolutegravir 50 mg, abacavir 600 mg/lamivudine 300 mg; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Purpura, Schoenlein-Henoch, Graft Versus Host Disease, Anemia, Hemolytic, Autoimmune, Rheumatoid Arthritis, Churg-Strauss Syndrome, Hypersensitivity Vasculitis, Wegener's Granulomatosis, Systemic Lupus Erythematosus, Giant Cell Arteritis, Pure Red Cell Aplasia, Juvenile Rheumatoid Arthritis, Polyarteritis Nodosa, Autoimmune Thrombocytopenic Purpura, Takayasu Arteritis
Interventions: anti-thymocyte globulin, cyclophosphamide, cyclosporine, filgrastim, methylprednisolone, prednisone, Autologous Peripheral Blood Stem Cell Transplantation; Drug · Procedure
Lead sponsor: Fairview University Medical Center; Other
Eligibility: 1 Year to 55 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: HIV Infections, Hepatitis C
Interventions: highly active antiretroviral therapy (HAART); Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Hepatitis C
Interventions: valopicitabine, pegylated interferon; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 65 Years
Timeline: Started 2004
U.S. locations: 2
States / cities: Bradenton, Florida • San Antonio, Texas

Conditions: COVID-19
Interventions: Dupilumab, Placebo; Biological · Drug
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Acute and Long Term Effects of COVID-19 on Systemic Inflammation, Acute and Long Term Effects of COVID-19 on Lung Function, Acute and Long Term Effects of COVID-19 on Cardiac Function, Acute and Long Term Effects of COVID-19 on Kidney Function, Acute and Long Term Effects of COVID-19 on Brain Function
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Hepatitis C
Interventions: Peginterferon Lambda-1a, Peginterferon Alfa-2a, Ribavirin, Daclatasvir, Telaprevir; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 444 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 8
States / cities: Long Beach, California • Marietta, Georgia • New York, New York + 5 more

Conditions: RSV Infection
Interventions: EDP-323, Placebo; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: HIV Infections
Interventions: gp160 Vaccine (Immuno-AG); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1993
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions: Azithromycin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 6
States / cities: Boston, Massachusetts • Syracuse, New York • The Bronx, New York + 3 more

Conditions: Diabetes, Wound Infection, Healthy Volunteers
Interventions: Tedizolid, Microdialysis Catheter Insertion; Drug · Procedure
Lead sponsor: Hartford Hospital; Other
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Malaria, Malaria,Falciparum
Interventions: PfSPZ Vaccine, PfSPZ Challenge (7G8), Normal Saline; Biological · Other
Lead sponsor: Sanaria Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: HIV Infections
Interventions: Indinavir sulfate; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 16 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 29
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 20 more

Conditions: Cardiovascular Diseases
Interventions: Gaming in a virtual environment; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 30 Years to 65 Years · Male only
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Orange, Connecticut

Conditions: HIV Infections, Acquired Immunodeficiency Syndrome, Medication Adherence
Interventions: MedCHEC Tablet Computer & Adherence Care; Behavioral
Lead sponsor: Boston University; Other
Eligibility: 18 Years and older
Enrollment: 371 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 3
States / cities: Los Angeles, California • Boston, Massachusetts

Conditions: Bacterial Infection, HIV
Interventions: SKIN Intervention, Treatment as Usual; Behavioral · Other
Lead sponsor: Butler Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 2
States / cities: Boston, Massachusetts • Providence, Rhode Island

Conditions: Infections, Urinary Tract, Nephrolithiasis
Interventions: Duration of antibiotics; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 99 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV-infection/Aids
Interventions: Peer Navigator; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older · Male only
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

Effect of Interleukin-2 on HIV Treatment Interruption

Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Chronic Fatigue of Post-COVID Condition

Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells

Impact of a Human Papilloma Virus (HPV) Vaccine in HIV-Infected Young Women

Surgical Site Infection With 0.05% Chlorhexidine (CHG) Compared to Triple Antibiotic Irrigation

Effects of MAC Preventive Therapy on Disease-Causing Bacteria in HIV-Infected Patients: A Substudy of CPCRA 048

Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets

Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases

The Impact of HAART on Response to Hepatitis C Treatment in Patients Taking Peginterferon Alpha-2b and Ribavirin

Valopicitabine When Administered Alone and in Combination With Interferon to Treatment-Naive Patients With Hepatitis C

Safety and Efficacy of Dupilumab for Treatment of Hospitalized COVID-19 Patients

Cardiopulmonary Inflammation and Multi-System Imaging During the Clinical Course of COVID-19 Infection in Asymptomatic and Symptomatic Persons

Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy

A Study of EDP-323 in Healthy Subjects

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived HIV-1 Recombinant Envelope Glycoprotein (gp160)

An Open, Multicenter, Randomized, Dose-Ranging Study of Azithromycin in the Treatment of Disseminated Mycobacterium Avium-Intracellulare Complex Infection (MAC) in Patients With Acquired Immune Deficiency Syndrome (AIDS)

Tedizolid Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis

A Phase 1 Trial of PfSPZ Vaccine in Healthy Adults to Determine Safety, Tolerability and Efficacy Against Heterologous CHMI

A Comparison of Two Dose Levels of Indinavir Combined With Two Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs) in HIV-Infected Patients

The LEARN Study for CVD Prevention

Medications for Chronic HIV: Education and Collaboration

Preventing Bacterial and Viral Infections Among Injection Drug Users

Preoperative Prophylactic Antibiotic Duration in Moderate to High Risk Ureteroscopy

Effectiveness of Peer Navigation to Link Released HIV+ Jail Inmates to HIV Care